Spectrum Pharmaceuticals Out-Licenses Rights for Greater China To CASI Pharmaceuticals For Three Of Its Drugs

By: via Benzinga
Spectrum receives a 19.99% stake (pre-transaction) in CASI, a NASDAQ-listed, oncology-focused Company with expertise and focus on ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.